ArticleToxics2025
Molecular Mechanism of Perfluorooctane Sulfonate-Induced Lung Injury Mediated by the Ras/Rap Signaling Pathway in Mice.
Article in Toxics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current Status of Per- and Poly-Fluoroalkyl Substances (PFAS) Exposure on Lung Cell Biology and Pulmonary Outcomes along Human Health Risk Assessment Steps.Current allergy and asthma reports · 2026Review
- Analysis of the effects of perfluorooctane sulfonate on COPD using network toxicology and molecular docking.iScience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Perfluorooctane sulfonate (PFOS), a persistent organic pollutant, has raised significant public health concerns because of its widespread environmental presence and potential toxicity. Epidemiological studies have linked PFOS exposure to respiratory diseases, but the underlying molecular mechanisms remain poorly understood. Male C57 BL/6J mice were divided into a control group receiving Milli-Q water, a low-dose PFOS group (0.2 mg/kg/day), and a high-dose PFOS group (1 mg/kg/day) administered via intranasal instillation for 28 days. Lung tissue transcriptome sequencing revealed significantly enriched differentially expressed genes in the Ras and Rap signaling pathways. Key genes including Rap1b, Kras, and BRaf as well as downstream genes, such as MAPK1 and MAP2K1, exhibited dose-dependent upregulation in the high-dose PFOS exposure group. Concurrently, the downstream effector proteins MEK, ERK, ICAM-1, and VEGFa were significantly elevated in bronchoalveolar lavage fluid (BALF). These alterations are mechanistically associated with increased oxidative stress, inflammatory cytokine release, and pulmonary tissue damage. The results indicated that PFOS-induced lung injury is likely predominantly mediated through the activation of the Rap1b- and Kras-dependent BRaf-MEK-ERK axis. These findings highlight the critical role of Ras/Rap signaling pathways in PFOS-associated respiratory toxicity and underscore the need to develop therapeutic interventions targeting these pathways to mitigate associated health risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.